Bogart Wealth LLC Raises Stock Holdings in Tempus AI, Inc. $TEM

Key Points

• Bogart Wealth LLC boosted its stake in Tempus AI by 365,087.5% in Q4, buying 58,414 shares to hold 58,430 shares valued at about $3.45 million.
• Insider selling has been heavy recently—insiders sold 397,591 shares worth $21.36 million in the last 90 days, including CEO Ryan Fukushima and Eric P. Lefkofsky, with insiders owning roughly 24.26% of the company.
• Large institutions like Vanguard hold substantial positions (10.26M shares, ~$605.8M) and analysts are mixed but on average rate Tempus AI a "Moderate Buy" with an average target of $71.36 versus the stock near ~$51.10.

Bogart Wealth LLC increased its position in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 365,087.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 58,430 shares of the company's stock after purchasing an additional 58,414 shares during the period. Bogart Wealth LLC's holdings in Tempus AI were worth $3,450,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Tempus AI by 8.7% in the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company's stock worth $605,772,000 after acquiring an additional 817,014 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Tempus AI by 1.2% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,504,823 shares of the company's stock worth $206,960,000 after acquiring an additional 41,728 shares during the last quarter. Voloridge Investment Management LLC grew its stake in shares of Tempus AI by 183.0% in the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company's stock worth $129,708,000 after acquiring an additional 1,039,176 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Tempus AI by 0.4% in the third quarter. Franklin Resources Inc. now owns 1,456,120 shares of the company's stock worth $117,523,000 after acquiring an additional 5,375 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Tempus AI by 312.7% in the third quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company's stock worth $102,869,000 after acquiring an additional 965,730 shares during the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Tempus AI news, CEO Ryan Fukushima sold 9,592 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $566,407.60. Following the transaction, the chief executive officer owned 694,354 shares of the company's stock, valued at approximately $41,001,603.70. This represents a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $46.38, for a total value of $7,710,675.00. Following the completion of the transaction, the chief executive officer directly owned 8,875,033 shares in the company, valued at approximately $411,624,030.54. This represents a 1.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 397,591 shares of company stock valued at $21,358,961 in the last 90 days. Insiders own 24.26% of the company's stock.

Tempus AI Stock Down 3.0%

TEM stock opened at $51.10 on Wednesday. Tempus AI, Inc. has a fifty-two week low of $41.73 and a fifty-two week high of $104.32. The business's 50-day moving average is $50.86 and its two-hundred day moving average is $63.73. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13. The company has a market cap of $9.14 billion, a price-to-earnings ratio of -36.24 and a beta of 4.90.

Analyst Ratings Changes

A number of research analysts have recently issued reports on TEM shares. JPMorgan Chase & Co. lowered their price target on Tempus AI from $80.00 to $60.00 and set a "neutral" rating on the stock in a report on Wednesday, February 25th. Needham & Company LLC reaffirmed a "buy" rating and set a $75.00 price target on shares of Tempus AI in a report on Wednesday, March 11th. HC Wainwright upped their price target on Tempus AI from $89.00 to $95.00 and gave the company a "buy" rating in a report on Monday, March 9th. TD Cowen raised Tempus AI from a "hold" rating to a "buy" rating and set a $65.00 price target on the stock in a report on Monday, April 13th. Finally, Jefferies Financial Group started coverage on Tempus AI in a report on Monday, April 13th. They set an "underperform" rating and a $35.00 price target on the stock. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Tempus AI has an average rating of "Moderate Buy" and an average target price of $71.36.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.